More tools:Markets·Screener·Research·Chat

NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) Financial Statements

NewAmsterdam Pharma Company N.V. Ordinary Shares
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG01BNNTQP2
XNAS · usd
25.63▲ 0.23 (0.91%)
As of 2026-09-08
Valuation
Market Cap
Enterprise Value
Trailing P/E—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close25.40
Day's Range23.24 – 26.19
52-Week Range23.05 – 42.21
Volume3.8M
Avg Volume1.2M
Share Statistics
Shares Outstanding
Employees100
ExchangeXNAS
Listed2022-11-23
Share count as of August 3, 2026
Loading Income Statement…
Key questions about NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS)
What is NewAmsterdam Pharma Company N.V. Ordinary Shares's Market Cap?
NewAmsterdam Pharma Company N.V. Ordinary Shares's Market Cap is $3.1B, based on as-reported figures from SEC (XBRL) filings.
What is NewAmsterdam Pharma Company N.V. Ordinary Shares's Enterprise Value?
NewAmsterdam Pharma Company N.V. Ordinary Shares's Enterprise Value is $2.4B, based on as-reported figures from SEC (XBRL) filings.
What is NewAmsterdam Pharma Company N.V. Ordinary Shares's Price / Sales?
NewAmsterdam Pharma Company N.V. Ordinary Shares's Price / Sales is 430.2×, based on as-reported figures from SEC (XBRL) filings.
What is NewAmsterdam Pharma Company N.V. Ordinary Shares's EV / Revenue?
NewAmsterdam Pharma Company N.V. Ordinary Shares's EV / Revenue is 341.2×, based on as-reported figures from SEC (XBRL) filings.
What is NewAmsterdam Pharma Company N.V. Ordinary Shares's EV / EBITDA?
NewAmsterdam Pharma Company N.V. Ordinary Shares's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is NewAmsterdam Pharma Company N.V. Ordinary Shares's Revenue (TTM)?
NewAmsterdam Pharma Company N.V. Ordinary Shares's Revenue (TTM) is $7.1M, based on as-reported figures from SEC (XBRL) filings.
What is NewAmsterdam Pharma Company N.V. Ordinary Shares's Net Income (TTM)?
NewAmsterdam Pharma Company N.V. Ordinary Shares's Net Income (TTM) is -$259.5M, based on as-reported figures from SEC (XBRL) filings.
What is NewAmsterdam Pharma Company N.V. Ordinary Shares's EBITDA?
NewAmsterdam Pharma Company N.V. Ordinary Shares's EBITDA is -$244.2M, based on as-reported figures from SEC (XBRL) filings.
What is NewAmsterdam Pharma Company N.V. Ordinary Shares's Diluted EPS (TTM)?
NewAmsterdam Pharma Company N.V. Ordinary Shares's Diluted EPS (TTM) is -2.17, based on as-reported figures from SEC (XBRL) filings.
What is NewAmsterdam Pharma Company N.V. Ordinary Shares's EBITDA Margin?
NewAmsterdam Pharma Company N.V. Ordinary Shares's EBITDA Margin is -3428.8%, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023
Revenue
YoY growth-80.7%+2.1%-99.7%-98.8%
Operating expenses:
Research and development expenses
Selling, general and administrative expenses
Total operating expenses
% of revenue1852.6%2021.7%206287.5%15945.7%
Operating loss
% of revenue-1752.6%-1921.7%-206187.5%-15845.7%
Other income (expense):
Interest income
Fair value change - earnout——
Fair value change - warrants
Foreign exchange gains/(losses)
Loss before tax
Income tax expense————
Loss for the period
% of revenue-1732.9%-1593.5%-234134.4%-20691.1%
Other comprehensive income/(loss)
Unrealized gain/(loss) on available-for-sale securities, net of tax
Total comprehensive loss for the period, net of tax
Net loss per ordinary share
Basic—
Diluted—